Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

61. A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury. (Full text)

A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury. Antiplatelet therapy is critical in the management of coronary artery diseases. For patients undergoing cardiac surgeries, including coronary artery bypass graft (CABG) and valve replacement, controversy remains in preoperative antiplatelet therapy concerning risk of bleeding. For safety concern, aspirin is recommended to be withdrawn 5 to 10 days before a cardiac (...) surgery. Recent studies, however, indicate that preoperative aspirin may have a protective effect on cardiac surgery-associated acute kidney injury (CSA-AKI).To estimate the efficacy of preoperative aspirin in preventing CSA-AKI.Eligible studies included randomized controlled trials (RCTs) and observational studies (OSs) of patients, who had undergone CABG, valve replacement, or combined surgery. These studies compared preoperative aspirin with placebo/no aspirin and reported the least incidence

2020 The heart surgery forum PubMed abstract

62. Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply. (Abstract)

Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply. 31184736 2019 06 19 2020 01 17 1538-3598 321 22 2019 06 11 JAMA JAMA Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply. 2244-2245 10.1001/jama.2019.4017 Zheng Sean L SL Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. Roddick Alistair J AJ Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. eng Journal Article Comment (...) United States JAMA 7501160 0098-7484 R16CO5Y76E Aspirin AIM IM JAMA. 2019 Jun 11;321(22):2243-2244 31184732 JAMA. 2019 Jun 11;321(22):2244 31184734 Aspirin Cardiovascular Diseases Hemorrhage Humans Primary Prevention 2019 6 12 6 0 2019 6 12 6 0 2019 6 20 6 0 ppublish 31184736 2735496 10.1001/jama.2019.4017

2020 JAMA

63. A comparison of aspirin against rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty: A meta-analysis. (Full text)

A comparison of aspirin against rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty: A meta-analysis. Total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients are at an elevated risk of post-operative venous thromboembolism (VTE). Newer thromboprophylactic agents such as rivaroxaban are increasingly used and effective in preventing thromboembolic events but may worsen bleeding risk. Recent studies have suggested that the more cost-effective aspirin (...) may also be effective in preventing VTE. This systematic review and meta-analysis aimed to compare the efficacy of aspirin against rivaroxaban for the prevention of VTE following TKA and THA.Electronic searches were performed using five databases from their date of inception to August 2018. Relevant studies were identified, with data extracted and meta-analyzed from the studies.Five studies were included, which consisted of 2257 in the aspirin group and 2337 in the rivaroxaban group. There were

2020 Journal of orthopaedic surgery (Hong Kong) PubMed abstract

64. Clinical Role of Aspirin in Mood Disorders: A Systematic Review. (Full text)

protective effects against depression in early cohort studies. This systematic review thus aimed to investigate the role of aspirin in mood disorders. Using the keywords (aspirin or acetylsalicy* or asa) and (mood or depress* or bipolar or mania or suicid*), a comprehensive search of PubMed, EMBASE, Medline, PsycINFO, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), Clinicaltrials.gov and Google Scholar databases found 13,952 papers published (...) Clinical Role of Aspirin in Mood Disorders: A Systematic Review. Worldwide, depression and bipolar disorder affect a large and growing number of people. However, current pharmacotherapy options remain limited. Despite adequate treatment, many patients continue to have subsyndromal symptoms, which predict relapse in bipolar illness and often result in functional impairments. Aspirin, a common nonsteroidal anti-inflammatory drug (NSAID), has purported beneficial effects on mood symptoms, showing

2020 Brain sciences PubMed abstract

65. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr (Abstract)

Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr Recently, three randomized trials reported that dual antithrombotic treatments (DATs) including non-vitamin K antagonist oral anticoagulants (NOACs) and a P2Y12 inhibitor without aspirin were associated with significantly less bleeding than

2020 Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

66. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. (Abstract)

Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. The publication of new trials brought additional data to the controversial topic of aspirin use in diabetic patients for primary prevention. Therefore, we aimed to systematically review all randomized controlled trials evaluating the clinical impact of aspirin in this setting.We searched for randomized controlled trials (RCTs) evaluating the impact of aspirin in patients

2019 Primary care diabetes

67. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: A systematic review and meta-analysis. (Abstract)

Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: A systematic review and meta-analysis. There is still insufficient data about the risk-benefit profile about recommending non-aspirin, non-steroidal anti-inflammatory drugs (NA-NSAIDs) for colorectal cancer (CRC) prevention, especially in people aged 40 years or older. This study specifically addressed the association between regular NA-NSAIDs use and CRC risk in the population aged

2019 Cancer epidemiology

68. Aspirin plus clopidogrel (Abstract)

Aspirin plus clopidogrel Objectives. Stroke is a common condition after a transient ischemic attack (TIA) or minor ischemic stroke (IS). Adding clopidogrel to aspirin may yield more beneficial outcomes than aspirin mono-therapy; meanwhile, the risk of bleeding in the acute phase remains poorly understood. Therefore, there is increasing emphasis on the risks and benefits of clopidogrel with aspirin compared with aspirin mono-therapy in an effort to treat TIA/IS. Design. We searched several (...) electronic databases, including PubMed, Cochrane, and Embase, to identify eligible randomized controlled trials (RCTs) based on the index words comparing dual-antiplatelet therapy to aspirin mono-therapy for secondary stroke prevention updated to December, 2018. Results. A total of 11 RCTs met our inclusion criteria. The pooled analysis showed that clopidogrel plus aspirin was associated with a trend toward a reduction in recurrent IS (RR = 0.72, 95%CI = 0.65-0.81, p < .001), but not the recurrent stroke

2019 Scandinavian cardiovascular journal : SCJ

69. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. (Abstract)

Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. Non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the proliferation of cholangiocarcinoma (CCA) cells in vitro through inhibition of cyclooxygenase-2. However, the effects of aspirin and NSAIDs on the risk of CCA remain unclear. We performed this meta-analysis to assess the risk of biliary tract cancers in patients who take aspirin and/or NSAIDs.A systematic review (...) was conducted utilizing MEDLINE, EMBASE, Cochrane databases from inception through October 2017 to identify studies that assessed the association of aspirin and/or NSAIDs use with risk of biliary tract cancers including CCA, gallbladder cancer and ampulla of Vater cancer. Effect estimates from the studies were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.Five observational studies with a total of 9 200 653 patients were enrolled. The pooled

2019 QJM : monthly journal of the Association of Physicians

70. Kaiser Permanente National Aspirin Clinician Guide

Kaiser Permanente National Aspirin Clinician Guide This Clinician Guide expires within two years of the posted month. 1 See National Clinical Library for current version (https://cl.kp.org). Aspirin Clinician Guide October 2018 Introduction These recommendations were developed to assist primary care physicians and other clinicians in aspirin use. The KP National Integrated Cardiovascular Health Guideline team adopted the 2016 aspirin recommendations developed by the United States Preventive (...) Services Task Force (USPSTF) on “Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication” for patients without Atherosclerotic Cardiovascular Disease (ASCVD). It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by practitioners. Aspirin Therapy at 81 mg Orally Daily for Adults without ASCVD Risk Assessment ? 10-year ASCVD Risk is risk of fatal or nonfatal myocardial infarctions or strokes in adults. A region may

2019 Kaiser Permanente National Guideline Program

71. Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies. (Abstract)

Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies. Considering the increased risk of bleeding caused by aspirin, and the observed benefit in all-cause mortality may be due to an improvement in cardiovascular-related mortality. We carried out this meta-analysis to estimate the association of low-dose aspirin use and risk of cancer-specific mortality.We searched the PubMed and China National Knowledge Infrastructure (CNKI) databases for all articles within (...) a range of published years from 1980 to 2018.Finally, 13 published cohort studies with 65 768 patients were available for estimating overall risk of cancer-specific mortality associating with post-diagnosis low-dose aspirin use, and 4 cohort studies were available for pre-diagnosis low-dose aspirin use with 16 654 patients. Overall, statistical evidence of significantly decreased cancer-specific mortality was found to be associated with post-diagnosis low-dose aspirin use (OR = 0.84, 95% CI = 0.75

2019 Journal of public health (Oxford, England)

72. A comparison of contemporary versus older studies of aspirin for primary prevention. (Full text)

A comparison of contemporary versus older studies of aspirin for primary prevention. Recent aspirin trials have not shown similar benefits for primary prevention as older studies.To compare benefits and harms of aspirin for primary prevention before and after widespread use of statins and colorectal cancer screening.We compared studies of aspirin for primary prevention that recruited patients from 2005 onward with previous individual patient data (IPD) meta-analyses that recruited patients from (...) ). There was no effect on all-cause mortality, cardiovascular mortality, fatal stroke or fatal MI.Per 1200 persons taking aspirin for primary prevention for 5 years, there will be 4 fewer MACEs, 3 fewer ischaemic strokes, 3 more intracranial haemorrhages and 8 more major bleeding events. Aspirin should no longer be recommended for primary prevention.© The Author(s) 2019. Published by Oxford University Press. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

2019 Family Practice PubMed abstract

73. Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials. (Abstract)

Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials. Numerous studies have investigated use of acetylsalicylic acid (ASA) for prevention of cardiovascular deaths. The vast majority of the work in this area has focused on secondary prevention. However, underuse of ASA still remains a major issue. Fewer studies have investigated the impact of ASA on primary prevention of cardiovascular death. A meta-analysis of individual (...) participant data from six randomized studies, published in 2009, showed decrease in serious vascular events but at the cost of causing increased bleeding and hemorrhagic stroke. Recent studies have raised a number of key questions regarding the benefits and risks of using ASA for primary prevention.

2019 European journal of preventive cardiology

74. Associations of candidate gene polymorphisms with poor responsiveness to aspirin: a meta-analysis. (Abstract)

Associations of candidate gene polymorphisms with poor responsiveness to aspirin: a meta-analysis. Recently, the roles of gene polymorphisms in poor responsiveness to aspirin were extensively investigated, with conflicting results. Therefore, we performed this meta-analysis to better assess the relationship between candidate genetic variants and poor responsiveness to aspirin. Eligible articles were searched in PubMed, Medline, Embase and CNKI. Odds ratios (ORs) with 95% confidence intervals (...) (CIs) were used to detect possible associations of gene polymorphisms with poor responsiveness to aspirin. Among 53 eligible articles, a total of 22 candidate gene polymorphisms were analyzed. A significant association with poor responsiveness to aspirin was observed for GP1BA rs2243093, PTGS1 rs1330344, PTGS2 rs689466 and TBXA2R rs1131882 polymorphisms in overall analyses. Further subgroup analyses demonstrated that ITGA2 rs1126643, PTGS1 rs1330344, PTGS2 rs20417, PTGS2 rs689466 and TBXA2R

2019 Clinical and experimental pharmacology & physiology

75. Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. (Abstract)

Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. 30019608 2019 11 20 2047-4881 26 2 2019 Jan European journal of preventive cardiology Eur J Prev Cardiol Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. 215-218 10.1177/2047487318788613 Khan Safi U SU 1 Guthrie Clinic, Robert Packer Hospital, USA. Talluri Swapna S 1 Guthrie Clinic

2019 European journal of preventive cardiology

76. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. (Abstract)

Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. 31070755 2019 11 15 2019 11 15 1460-2393 112 9 2019 Sep 01 QJM : monthly journal of the Association of Physicians QJM Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. 719-720 10.1093/qjmed/hcz099 Du M-H MH Emergency Department, Wan Fang Hospital. Department of Emergency, School of Medicine, College of Medicine. Chu K C-W (...) Anti-Inflammatory Agents, Non-Steroidal R16CO5Y76E Aspirin IM QJM. 2019 Jun 1;112(6):421-427 30753687 QJM. 2019 Sep 1;112(9):721-722 31070749 Anti-Inflammatory Agents, Non-Steroidal Aspirin Bile Duct Neoplasms Bile Ducts, Intrahepatic Cholangiocarcinoma Humans 2019 5 10 6 0 2019 11 16 6 0 2019 5 10 6 0 ppublish 31070755 5487418 10.1093/qjmed/hcz099

2019 QJM : monthly journal of the Association of Physicians

77. Reply to: Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. (Abstract)

Reply to: Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. 31070749 2019 11 15 2019 11 15 1460-2393 112 9 2019 Sep 01 QJM : monthly journal of the Association of Physicians QJM Reply to: Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. 721-722 10.1093/qjmed/hcz103 Lapumnuaypol K K Department of Internal Medicine, Albert Einstein Medical Center, PA, USA. Tiu (...) . Cheungpasitporn W W Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. eng Letter Comment England QJM 9438285 1460-2393 0 Anti-Inflammatory Agents, Non-Steroidal R16CO5Y76E Aspirin IM QJM. 2019 Sep 1;112(9):719-720 31070755 Anti-Inflammatory Agents, Non-Steroidal Aspirin Bile Duct Neoplasms Bile Ducts, Intrahepatic Cholangiocarcinoma Humans 2019 5 10 6 0 2019 11 16 6 0 2019 5 10 6 0 ppublish 31070749 5487417 10.1093/qjmed/hcz103

2019 QJM : monthly journal of the Association of Physicians

78. Reply to: 'Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis'. (Abstract)

Reply to: 'Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis'. 30907969 2019 11 15 2019 11 15 1460-2393 112 8 2019 Aug 01 QJM : monthly journal of the Association of Physicians QJM Reply to: 'Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis'. 645 10.1093/qjmed/hcz075 Lapumnuaypol K K From the Department of Internal Medicine, Albert Einstein Medical Center, 5501 Old York (...) of Medicine Siriraj hospital, Mahidol University, 2 Thanon Wang Lang, Khwaeng Siriraj, Khet Bangkok Noi, Krung Thep Maha Nakhon, Thailand. Mao M A MA Department of Nephrology, Nephrology and Hypertension, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. Cheungpasitporn W W Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, USA. eng Letter Comment England QJM 9438285 1460-2393 0 Anti-Inflammatory Agents, Non-Steroidal R16CO5Y76E Aspirin IM

2019 QJM : monthly journal of the Association of Physicians

79. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin (Full text)

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding.This study sought to explore the effects of the combination of rivaroxaban and aspirin compared with aspirin on sites, timing (...) to the combination of rivaroxaban and aspirin or to aspirin alone and followed for a mean of 23 months. Compared with aspirin alone, the combination increased modified International Society on Thrombosis and Hemostasis major bleeding (288 of 9,152 [3.1%] vs. 170 of 9,126 [1.9%]), (HR: 1.70; 95% CI: 1.40 to 2.05; p < 0.001), International Society on Thrombosis and Hemostasis major bleeding (206 of 9,152 [2.3%] vs. 116 of 9,126 [1.3%]), (HR: 1.78; 95% CI: 1.41 to 2.23; p < 0.0001), and minor bleeding (838 of 9,152

2019 EvidenceUpdates PubMed abstract

80. A meta-analysis comparing aspirin alone versus dual antiplatelet therapy for the prevention of venous graft failure following coronary artery bypass surgery. (Abstract)

A meta-analysis comparing aspirin alone versus dual antiplatelet therapy for the prevention of venous graft failure following coronary artery bypass surgery. Aspirin (ASA) monotherapy is the current standard of care after coronary artery bypass grafting (CABG) to prevent saphenous vein graft (SVG) failure. Several small, randomized clinical trials (RCTs) have suggested that dual antiplatelet therapy (DAPT) may be more effective at preventing SVG failure than ASA alone; however, it is unclear (...) whether some P2Y12 inhibitors are more effective than others for the prevention of SVG failure.Scientific databases and websites were searched to find RCTs. Both traditional pairwise meta-analysis using random-effect model and network meta-analysis using mixed-treatment comparison models were performed to compare the efficacy of various anti-platelet strategies for the prevention of SVG failure.Nine RCTs, which included a total of 1677 patients, were analyzed. Compared to ASA alone, DAPT decreased

2019 Cardiovascular revascularization medicine : including molecular interventions